Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination

References

• KannelWBGordonTSchwartzMJSystolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham studyAm J Cardiol1971273353465572576
   PubMed Web of Science ®Google Scholar
• MacMahonSPetoRCutlerJBlood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution biasLancet19903357657741969518
   PubMed Web of Science ®Google Scholar
• StamlerJStamlerRNeatonJDBlood pressure, systolic and diastolic, and cardiovascular risks. US population dataArch Intern Med19931535986158439223
   PubMed Web of Science ®Google Scholar
• StaessenJAGasowskiJWangJGRisks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trialsLancet200035586587210752701
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRfor the Prospective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studiesLancet2002143601903191312493255
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 reportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• WhitworthJAChalmersJWorld Health Organization – International Society of Hypertension (WHO/ISH) hypertension guidelinesClin Exp Hypertens20042674775215702630
   PubMed Web of Science ®Google Scholar
• 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens2007251751176217762635
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens20072591751176217762635
   PubMed Web of Science ®Google Scholar
• KannelWBGordonTSchwartzMJSystolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham studyAm J Cardiol1971273353465572576
   PubMed Web of Science ®Google Scholar
• LawesCMBennettDALewingtonSRodgersABlood pressure and coronary heart disease: A review of the evidenceSemin Vasc Med2002235536816222626
   PubMedGoogle Scholar
• StamlerJStamlerRNeatonJDBlood pressure, systolic and diastolic, and cardiovascular risks. US population dataArch Intern Med19931535986158439223
   PubMed Web of Science ®Google Scholar
• BenetosAThomasFBeanKGautierSSmulyanHGuizeLPrognostic value of systolic and diastolic blood pressure in treated hypertensive men: ClarificationArch Intern Med200316312112523931
   PubMedGoogle Scholar
• WhiteWBCardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rateBlood Press Monit20016637211433126
   PubMed Web of Science ®Google Scholar
• ManciaGFerrariAGregoriniLBlood pressure and heart rate variabilities in normotensive and hypertensive human beingsCirc Res198353961046861300
   PubMed Web of Science ®Google Scholar
• PalatiniPPenzoMRacioppaAClinical relevance of nighttime blood pressure and of daytime blood pressure variabilityArch Intern Med1992152185518601387782
   PubMed Web of Science ®Google Scholar
• SanderDKlingelhoferJDiurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosisNeurology1996475005078757028
   PubMed Web of Science ®Google Scholar
• SanderDKlingelhoferJEarly carotid atherosclerosis of the internal and external carotid artery related to twenty-four-hour blood pressure variabilityCerebrovasc Dis19977338344
   Web of Science ®Google Scholar
• LuscherTSVanhouttePMThe endothelium: Modulator of cardiovascular functionBoca Raton, FLCRC Press1990
   Google Scholar
• RossRThe pathogenesis of atherosclerosis: A perspective for the 1990sNature19933628018098479518
   PubMed Web of Science ®Google Scholar
• MatteiPVirdisAGhiadoniLTaddeiSSalvettiAEndothelial function in hypertensionJ Nephrol1997101921979377726
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAGhiadoniLSudanoISalvettiAEffects of antihypertensive drugs on endothelial dysfunction: Clinical implicationsDrugs20026226528411817973
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAGhiadoniLMagagnaASalvettiAVitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertensionCirculation199897222222299631871
   PubMed Web of Science ®Google Scholar
• CaiHHarrisonDGEndothelial dysfunction in cardiovascular diseases: The role of oxidant stressCirc Res20008784084411073878
   PubMed Web of Science ®Google Scholar
• StankeviciusEMartinezACMulvanyMJSimonsenUBlunted acetylcholine relaxation and nitric oxide release in arteries from renal hypertensive ratsJ Hypertens2002201571157912172319
   PubMed Web of Science ®Google Scholar
• VallancePCollerJMoncadaSEffects of endothelium-derived nitric, 22 oxide on peripheral arteriolar tone in manLancet1989299710002572793
   PubMed Web of Science ®Google Scholar
• VitaJATreasureCBNabelEGCoronary vasomotor response to acetylcholine relates to risk factors for coronary artery diseaseCirculation1990814914972105174
   PubMed Web of Science ®Google Scholar
• KugaTEgashiraKMohriMBradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivoCirculation1995921831897600649
   PubMed Web of Science ®Google Scholar
• LinderLKiowskiWBuhlerFRLuscherTFIndirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: Blunted response in essential hypertensionCirculation199081176217672344673
   PubMed Web of Science ®Google Scholar
• PanzaJAQuyyumiAABrushJEJrEpsteinSEAbnormal endothelium dependent vascular relaxation in patients with essential hypertensionN Engl J Med199032322272355955
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAMatteiPSalvettiAVasodilation to acetylcholine in primary and secondary forms of human hypertensionHypertension1993219299338505103
   PubMed Web of Science ®Google Scholar
• PanzaJAGarcmaCEKilcoyneCMQuyyumiACannonROIIIImpaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a single signal transduction pathwayCirculation199591173217387882481
   PubMed Web of Science ®Google Scholar
• BautistaLEInflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidenceJ Hum Hypertens20031722323012692566
   PubMed Web of Science ®Google Scholar
• CerielloAAssaloniRDa RosREffect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patientsCirculation20051112518252415867169
   PubMed Web of Science ®Google Scholar
• GhiadoniLMagagnaAVersariDDifferent effect of antihypertensive drugs on conduit artery endothelial functionHypertension2003411281128612719441
   PubMed Web of Science ®Google Scholar
• CetinkalpSSKaradenizMMErdoganMAOzgenGAYilmazCOShort-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetesSaudi Med J2008291414141818946564
   PubMed Web of Science ®Google Scholar
• WeekersLKrzesinskiJMClinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: Results of the IDNT and RENAAL trialsRev Med Liege20015672372611765585
   PubMedGoogle Scholar
• BramlagePDurand-ZaleskiIDesaiNPirkOHackerCThe value of irbesartan in the management of hypertensionExpert Opin Pharmacother2009101817183119601700
   PubMed Web of Science ®Google Scholar
• von zur MühlenBKahanTHäggAMillgårdJLindLTreatment with irbesartan or atenolol improves endothelial function in essential hypertensionJ Hypertens2001191813181811593101
   PubMed Web of Science ®Google Scholar
• SchäferAFraccarolloDTasPSchmidtIErtlGBauersachsJEndothelial dysfunction in congestive heart failure: ACE inhibition vs angiotensin II antagonismEur J Heart Fail2004615115914984722
   PubMed Web of Science ®Google Scholar
• VachharajaniNNShyuWCChandoTJEverettDWGreeneDSBarbhaiyaRHOral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in manJ Clin Pharmacol1998387027079725545
   PubMed Web of Science ®Google Scholar
• RitschelWAGerontokineticsCaldwell, NJTelford Press1988
   Google Scholar
• SicaDAMarinoMRHammettJLFerreiraIFordNFPharmacokinetics of irbesartan are not altered by renal impairment or hemodialysisClin Pharmacol Ther199762902909
   Web of Science ®Google Scholar
• VachharajaniNNShyuWCManthaSParkJSGreeneDSBarbhaiyaRHLack of effect of food on the oral bioavailability of irbesartan in healthy male volunteersJ Clin Pharmacol1998384334369602956
   PubMed Web of Science ®Google Scholar
• VachharajaniNShyuWCSmithRADouglasSGreeneDSThe effects of age and gender on the pharmacokinetics of irbesartanJ Clin Pharmacol199846611613
   Web of Science ®Google Scholar
• CazaubonCGougatJBousquetFPharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonistJ Pharmacol Exp Ther19932658268348496828
   PubMed Web of Science ®Google Scholar
• O’DonnellMPCraryGSOdaHKasiskeBLPowellJRKeaneWFIrbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitusKidney Int Suppl199763S218S2209407464
   PubMed Web of Science ®Google Scholar
• FogariRAmbrosoliSCorradiL24-Hour blood pressure control by once daily irbesartan as assessed by ambulatory blood pressure monitoringJ Hypertens199715151115189431859
   PubMed Web of Science ®Google Scholar
• MugelliniAPretiPZoppiAEffect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitusJ Hum Hypertens20041868769115071488
   PubMed Web of Science ®Google Scholar
• SchmiederRESchwertfegerMBramlagePSignificance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practiceVasc Health Risk Manag20095991100019997579
   PubMedGoogle Scholar
• BobrieGDeloncaJMoulinCGiacominoAPostel-VinayNAsmarRComparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) InvestigatorsAm J Hypertens2005181482148816280286
   PubMed Web of Science ®Google Scholar
• BramlagePFixed combination of irbesartan and hydrochlorothiazide in the management of hypertensionVasc Health Risk Manag2009521322419436667
   PubMedGoogle Scholar
• DerosaGCiceroAFGaddiAMugelliniACiccarelliLFogariREffects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertensionJ Cardiovasc Pharmacol20054559960415897788
   PubMed Web of Science ®Google Scholar
• NeutelJMGerminoFWSmithDComparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertensionJ Renin Angiotensin Aldosterone Syst20056848916470487
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEfficacy and safety of two treatment combinations of hypertension in very elderly patientsArch Gerontol Geriatr20094840140518457886
   PubMed Web of Science ®Google Scholar
• LarochellePFlackJMMarburyTCSareliPKriegerEMReevesRAEffects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter InvestigatorsAm J Cardiol199780161316159416950
   PubMed Web of Science ®Google Scholar
• CocaACalvoCGarcía-PuigJA multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: The MAPAVEL StudyClin Ther20022412613811833827
   PubMed Web of Science ®Google Scholar
• ManciaGKorliparaKvan RossumPVillaGSilvertBAn ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartanBlood Press Monit2002713514212048432
   PubMed Web of Science ®Google Scholar
• BrosnanMJHamiltonCAGrahamDLygateCAJardineEDominiczakAFIrbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone ratsJ Hypertens20022028128611821713
   PubMed Web of Science ®Google Scholar
• WilminkHWBangaJDHijmeringMErkelensWDStroesESRabelinkTJEffect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial functionJ Am Coll Cardiol19993414014510400003
   PubMed Web of Science ®Google Scholar
• CerielloAAssaloniRDa RosREffect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patientsCirculation20051112518252415867169
   PubMed Web of Science ®Google Scholar
• Kassler-TaubKLittlejohnTElliottWfor the Irbesartan/Losartan Study InvestigatorsComparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertensionAm J Hypertension199811445453
   PubMed Web of Science ®Google Scholar
• RossingKSchjoedtKJensenBRBoomsmaFParvingH-HEnhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKidney Int2005681190119816105050
   PubMed Web of Science ®Google Scholar
• PolóniaJDiogoDCaupersPDamascenoAInfluence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt dietJ Cardiovasc Pharmacol2003429810412827033
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRSteen AndersenSArnerPfor the Irbesartan in Patients with type 2 Diabetes and Microalbuminuria Study GroupThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med200134587087811565519
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• SassoFCCarbonaraOPersicoMIrbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertensionDiabetes Care2002251909191312401731
   PubMed Web of Science ®Google Scholar
• MorawietzHErbsSHoltzJEndothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: The EPAS trialCirculation20061141 SupplI296I30116820589
   PubMed Web of Science ®Google Scholar
• NavalkarSParthasarathySSantanamNKhanBVIrbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosisJ Am Coll Cardiol20013744044411216960
   PubMed Web of Science ®Google Scholar
• KhanBVNavalkarSKhanQARahmanSTParthasarathySIrbe-sartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery diseaseJ Am Coll Cardiol2001381662166711704378
   PubMed Web of Science ®Google Scholar